Please assess the completion status of the following clinical trial:

Trial Title: Study of Chitosan for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion:~1. Confirmation of adenocarcinoma of the prostate that is documented by one of the following: pathology report or clinic note with documented history of prostate cancer.~2. Subjects must be receiving ADT with a GnRH agonist or antagonist, with or without an anti-androgen or testosterone synthesis inhibitor. The current testosterone level must be documented to be \<50ng/dL at enrollment. Subjects whose ADT is interrupted may enroll or continue on study as long as the testosterone is documented to remain \<50ng/dL for the entire duration of study participation. Subjects who have undergone orchiectomy are also eligible.~3. Subjects must have adequate hematologic, renal, and hepatic function at baseline, as follows:~   * Hematology parameters: ANC \>1000/mcL, platelets \> 100,000/mcL, Hgb \>8.0gm/dL~  * Renal Function: eGFR of ≥ 45mls/min using Cockgroft and Gault formula~  * Liver Function: Total bilirubin ≤ULN, AST and ALT \<1.5x ULN~4. Able to swallow and retain oral medication~5. ECOG performance status of 0 - 2~6. Ability to sign written informed consent~7. Testosterone level \<50ng/dL at time of enrollment.~8. Age 18 or older.~9. May have had prior radiation therapy, surgery, or cryoablation for primary prostate cancer~10. May have had prior cytotoxic chemotherapy for metastatic prostate cancer, prior treatment with genomically-targeted agents, or Provenge~Exclusion:~1. Known allergy to chitosan or shellfish.~2. History of receiving more than 2 classes of ADT.~3. Chronic constipation (BM \< 3x weekly), history of malabsorption or history of daily laxative use.~4. Patients requiring medication administration with lunch or dinner or at a frequency of three or more times per day are not eligible.~5. Current use of chitosan, sevelamer, and/or glucosamine.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chitosan dose escalation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).